{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:44:35Z","timestamp":1794717875205,"version":"4.9.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.diabres.2024.111891","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T11:00:58Z","timestamp":1728990058000},"page":"111891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Role of MASLD in CVD: A review of emerging treatment options"],"prefix":"10.1016","volume":"217","author":[{"given":"Rocco","family":"Mollace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Nardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Tavernese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cardamone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2024.111891_b0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","article-title":"Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Mellemkj\u00e6r","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.diabres.2024.111891_b0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.diabres.2024.111891_b0015","doi-asserted-by":"crossref","unstructured":"Longo S, Menghini R, Federici M. Gut microbiota and type 2 diabetes mellitus. \u201cGut microbiome, microbial metabolites and cardiometabolic risk MRW series: Endocrinology Springer Nature Switzerland AG 2023 1. https:\/\/doi.org\/10.1007\/978-3-031-08115-6_8-1.","DOI":"10.1007\/978-3-031-08115-6_8-1"},{"issue":"4","key":"10.1016\/j.diabres.2024.111891_b0020","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.diabres.2024.111891_b0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.13793","article-title":"MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials","volume":"296","author":"Zannad","year":"2024","journal-title":"J Intern Med"},{"issue":"11","key":"10.1016\/j.diabres.2024.111891_b0030","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2024.111891_b0035","doi-asserted-by":"crossref","unstructured":"Zhou XD, Cai J, Targher G, Byrne CD, Shapiro MD, Sung KC, Somers VK, Chahal CAA, George J, Chen LL, Zhou Y, Zheng MH; CHESS-MAFLD consortium. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol 2022;21(1):270. doi: 10.1186\/s12933-022-01697-0.","DOI":"10.1186\/s12933-022-01697-0"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2024.111891_b0040","first-page":"S10","article-title":"Pathogenesis of MASLD and MASH \u2013 role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.diabres.2024.111891_b0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11906-023-01242-8","article-title":"Mechanisms linking metabolic-associated fatty liver disease (MAFLD) to cardiovascular disease","volume":"25","author":"Badmus","year":"2023","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"10.1016\/j.diabres.2024.111891_b0050","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2024.111891_b0055","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2024.111891_b0060","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/liv.12552","article-title":"Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance","volume":"35","author":"Kwak","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.diabres.2024.111891_b0065","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jama.2018.14854","article-title":"The physical activity guidelines for Americans","volume":"320","author":"Piercy","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2024.111891_b0070","first-page":"12","article-title":"Types of physical activity in nonalcoholic fatty liver disease and all-cause and cardiovascular mortality","volume":"2023","author":"Kim","year":"1923","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.diabres.2024.111891_b0075","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0041-1723751","article-title":"Effects of mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials","volume":"41","author":"Kawaguchi","year":"2021","journal-title":"Semin Liver Dis"},{"issue":"8","key":"10.1016\/j.diabres.2024.111891_b0080","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/obr.12857","article-title":"Impacts of carbohydrate-restricted diets on micronutrient intakes and status: a systematic review","volume":"20","author":"Churuangsuk","year":"2019","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabres.2024.111891_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2563","article-title":"Seeing double: the low carb diet","volume":"346","author":"McKenna","year":"2013","journal-title":"BMJ"},{"issue":"32","key":"10.1016\/j.diabres.2024.111891_b0090","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.diabres.2024.111891_b0095","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.3390\/jcm12175597","article-title":"Nonalcoholic fatty liver disease in patients with type 2 diabetes: screening, diagnosis, and treatment","volume":"12","author":"Ciardullo","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabres.2024.111891_b0100","doi-asserted-by":"crossref","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2023. Diabetes Care 2023;46(Suppl 1):S49-S67. doi: 10.2337\/dc23-S004. Erratum in: Diabetes Care 2023;46(9):1722. doi: 10.2337\/dc23-er09a. Erratum in: Diabetes Care. 2023;46(9):1718-1720. doi: 10.2337\/dc23-ad09.","DOI":"10.2337\/dc23-ad09"},{"issue":"6","key":"10.1016\/j.diabres.2024.111891_b0105","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL)","year":"2016","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.diabres.2024.111891_b0110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.diabres.2024.111891_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101182","article-title":"Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): pathways of action of hypoglycemic agents","volume":"29","author":"Maldonado-Rojas","year":"2024","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.diabres.2024.111891_b0120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s13340-016-0302-y","article-title":"The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus","volume":"8","author":"Bando","year":"2017","journal-title":"Diabetol Int"},{"key":"10.1016\/j.diabres.2024.111891_b0125","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/hepr.12834","article-title":"Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus","volume":"47","author":"Seko","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.diabres.2024.111891_b0130","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2169\/internalmedicine.2566-18","article-title":"The long-term efficacy of sodium glucose co-transporter 2 inhibitor in patients with non-alcoholic fatty liver disease","volume":"58","author":"Yamashima","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.diabres.2024.111891_b0135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2024.111891_b0140","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.2169\/internalmedicine.4398-19","article-title":"SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: the long-term effects on clinical features and liver histopathology","volume":"59","author":"Akuta","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.diabres.2024.111891_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.diabres.2024.111891_b0150","doi-asserted-by":"crossref","DOI":"10.2337\/dc21-1953","article-title":"Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes","author":"Pradhan","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2024.111891_b0155","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jgh3.12473","article-title":"Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes","volume":"5","author":"Sinha","year":"2021","journal-title":"JGH Open"},{"key":"10.1016\/j.diabres.2024.111891_b0160","article-title":"The safety and efficacy evaluation of Sodium-Glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty Liver disease: an updated meta-analysis","volume":"5","author":"Mo","year":"2021","journal-title":"Dig. Liver Dis."},{"issue":"4","key":"10.1016\/j.diabres.2024.111891_b0165","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/liv.15851","article-title":"Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: beyond their antidiabetic use","volume":"44","author":"Siafarikas","year":"2024","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.diabres.2024.111891_b0170","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00592-023-02088-x","article-title":"Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, obesity, and diabetes","volume":"60","author":"Longo","year":"2023","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabres.2024.111891_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241511971","article-title":"Gut microbiota composition and cardiovascular disease: a potential new therapeutic target?","volume":"24","author":"Belli","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.diabres.2024.111891_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015473","article-title":"Metabolic-dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments","volume":"24","author":"Yanai","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabres.2024.111891_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/biom13121695","article-title":"Beyond the cardiovascular effects of glucagon-like peptide-1 receptor agonists: body slimming and plaque stabilization. Are new statins born?","volume":"13","author":"Lecis","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.diabres.2024.111891_b0190","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular out- comes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.diabres.2024.111891_b0195","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.diabres.2024.111891_b0200","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diabres.2024.111891_b0205","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.numecd.2021.08.039","article-title":"Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society","volume":"31","author":"Napoli","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.diabres.2024.111891_b0210","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.diabres.2024.111891_b0215","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Retatrutide phase 2 obesity trial investigators. triple-hormone-receptor agonist retatrutide for obesity \u2013 a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"9756","key":"10.1016\/j.diabres.2024.111891_b0220","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2024.111891_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"eBioMedicine"},{"issue":"10","key":"10.1016\/j.diabres.2024.111891_b0230","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1080\/15548627.2017.1356977","article-title":"Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEBmediated activa- tion of autophagy and NLRP3 inflammasome inhibition","volume":"13","author":"Kim","year":"2017","journal-title":"Autophagy"},{"issue":"4","key":"10.1016\/j.diabres.2024.111891_b0235","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2024.111891_b0240","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12916-022-02288-2","article-title":"Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)","volume":"20","author":"Cho","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.diabres.2024.111891_b0245","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-017-0818-x","article-title":"Pemafibrate: first global approval","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.diabres.2024.111891_b0250","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of pemafibrate, a novel selective ppar\u03b1 modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2024.111891_b0255","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-021-01291-w","article-title":"Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials","volume":"20","author":"Yokote","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2024.111891_b0260","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.trsl.2016.08.006","article-title":"Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress","volume":"180","author":"Li","year":"2017","journal-title":"Transl Res"},{"key":"10.1016\/j.diabres.2024.111891_b0265","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0168-8278(99)80243-8","article-title":"A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis","volume":"31","author":"Basaranoglu","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2024.111891_b0270","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1210\/jc.2009-1487","article-title":"Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome","volume":"95","author":"Belfort","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2024.111891_b0275","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/13543784.2021.1951701","article-title":"Anti-diabetic drugs and NASH: From current option to promisingperspectives","volume":"30","author":"Smati","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"#cr-split#-10.1016\/j.diabres.2024.111891_b0280.1","unstructured":"Medicine N-NLo. Phase 3 study to evaluate the efficacy and safety of elafibranor versus placebo in patients with nonalcoholic steatohepatitis (NASH) (RESOLVE- IT) 2022 [updated 2022-03-23"},{"key":"#cr-split#-10.1016\/j.diabres.2024.111891_b0280.2","unstructured":"cited 2023 11\/09-2023]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02704403."},{"key":"10.1016\/j.diabres.2024.111891_b0285","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1021\/acs.jmedchem.7b01285","article-title":"Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) alpha\/gamma\/delta triple activators: discovery of lanifi- branor, a new antifibrotic clinical candidate","volume":"61","author":"Boubia","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.diabres.2024.111891_b0290","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2024.111891_b0295","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.diabres.2024.111891_b0300","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8416578","article-title":"Bile acids and the microbiome: making sense of this dynamic relationship in their role and management in Crohn\u2019s disease","volume":"2022","author":"Kumar","year":"2022","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2024.111891_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic statohepatitis: Interim analysis from multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2024.111891_b0310","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.08005","article-title":"Deciphering the nuclear bile acid receptor FXR paradigm","volume":"8","author":"Modica","year":"2010","journal-title":"Nucl Recept Signal"},{"key":"10.1016\/j.diabres.2024.111891_b0315","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2147\/TCRM.S113052","article-title":"New developments in the treatment of primary biliary cholangitis\u2014role of obeticholic acid","volume":"13","author":"Jhaveri","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.diabres.2024.111891_b0320","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2024.111891_b0325","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1055\/a-0623-2909","article-title":"An overview of FGF19 and FGF 21: the therapeutic role in treatment of the metabolic disorders and obesity","volume":"50","author":"Babaknejad","year":"2018","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.diabres.2024.111891_b0330","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.diabres.2024.111891_b0335","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2024.111891_b0340","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1665-2681(19)31539-X","article-title":"Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial","volume":"10","author":"Van Wagner","year":"2011","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.diabres.2024.111891_b0345","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1001\/jama.292.14.1724","article-title":"Bariatric surgery: a systematic review and meta-analysis","volume":"292","author":"Buchwald","year":"2004","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.diabres.2024.111891_b0350","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/dom.12922","article-title":"Short- and long-term mortality after bariatric surgery: a systematic review and meta-analysis","volume":"19","author":"Cardoso","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.diabres.2024.111891_b0355","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.soard.2020.11.004","article-title":"Safety of metabolic and bariatric surgery in obese patients with liver cirrhosis: a systematic review and meta-analysis","volume":"17","author":"Agarwal","year":"2021","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabres.2024.111891_b0360","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5152\/tjg.2019.17877","article-title":"Intragastric balloon treatment of obesity: long-term results and patient satisfaction","volume":"30","author":"I Haddad","year":"2019","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.diabres.2024.111891_b0365","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.gie.2020.08.023","article-title":"Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty","volume":"93","author":"Hajifathalian","year":"2021","journal-title":"Gastrointest Endosc"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724008015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724008015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:09:53Z","timestamp":1747400993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822724008015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":74,"alternative-id":["S0168822724008015"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111891","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of MASLD in CVD: A review of emerging treatment options","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111891"}}